ACHN
Achillion Pharmaceuticals, Inc.
ACHN
ACHN
Delisted
ACHN was delisted on the 27th of January, 2020.
121 hedge funds and large institutions have $164M invested in Achillion Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
121
Holders Change
-16
Holders Change %
-11.68%
% of All Funds
2.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
40
Reduced
40
Closed
27
Calls
$1.17M
Puts
$171K
Net Calls
+$998K
Net Calls Change
+$625K
Top Buyers
| 1 |
MCO
MAK Capital One
New York
|
+$5.16M |
| 2 |
AC
Armistice Capital
New York
|
+$3.66M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.09M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.09M |
| 5 |
Two Sigma Investments
New York
|
+$1.79M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.5M |
| 2 |
NC
Nexthera Capital
New York
|
-$5.83M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.92M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$4.71M |
